More stock at the high end: SailPoint (SAIL), an identity software provider, upsized its IPO to 60.0 million shares – up from 50.0 million shares in the prospectus – and priced the IPO at $23.00 – the top of its $21.00-to-$23.00 price range – to raise $1.38 billion on Wednesday night, Feb. 12, 2025. Of the […]
February 13, 2025 Read MoreSail on: SailPoint (SAIL Proposed), an identity security software company, leads this week’s IPO Calendar of about $2.0 billion in deals in the countdown to Valentine’s Day on Friday, Feb. 14, 2025. SailPoint increased its price range to $21.00 to $23.00 – up from $19.00 to $21.00 originally – in an SEC filing early today […]
February 11, 2025 Read MoreGo bigger and higher: Sionna Therapeutics (SION), a cystic fibrosis-focused biotech, upsized its IPO at pricing to 10.59 million shares – up from 8.82 million shares – and priced its IPO at $18.00 – the high end of its $16.00-to-$18.00 range – to raise $190.59 million on Thursday night, Feb. 6, 2025. At pricing, the […]
February 7, 2025 Read MoreTitan America (TTAM) priced its IPO at $16.00 – matching the price talk and below the mid-point of its $15.00-to-$18.00 range – and sold 24.0 million shares – the number in the prospectus – to raise $384.0 million on Thursday night, Feb. 6, 2025. At pricing, Titan America had a market cap of about $2.95 […]
Read MoreIdentity security software company SailPoint (SAIL Proposed) unveiled the terms and launched its $1 billion IPO early today – Tuesday, Feb. 4, 2025: 50.0 million shares at a price range of $19 to $21 a share. Of the 50.0 million shares in the IPO, the company is offering 47.5 million shares and the selling shareholders […]
February 4, 2025 Read MoreCystic fibrosis-focused biotech Sionna Therapeutics (SION Proposed) unveiled its IPO terms early today on the first business day in February 2025. Sionna Therapeutics intends to offer 8.82 million shares – at a price range of $16.00 to $18.00 – to raise $150.0 million, according to an S-1/A filing early today – Monday, Feb. 3, 2025. […]
February 3, 2025 Read MoreMore stock – priced at the mid-point: Maze Therapeutics (MAZE), a biotech developing drugs to treat chronic kidney disease (CKD), increased its IPO’s size – to 8.75 million shares – up from 7.8 million shares in the prospectus – and priced its IPO at $16.00 – the mid-point of its $15.00-to-$17.00 price range – to raise […]
January 31, 2025 Read MoreMetsera (MTSR), the developer of a weight-loss shot, priced its IPO at $18.00 – $1.00 above the top of its $15.00-to-$17.00 price range – on Thursday night, Jan. 30, 2025. The New York biotech, however, trimmed the IPO’s size at pricing to 15.28 million shares – down from 17.19 million shares in the prospectus – […]
January 30, 2025 Read MoreInfinity Natural Resources (INR), an oil and natural gas producer involved in fracking in Ohio and Pennsylvania, priced its IPO at $20.00 – $1.00 below the top of its $18.00-to-$21.00 price range – on Thursday night, Jan. 30, 2025. Infinity Natural Resources sold 13.25 million shares – the number of shares in the prospectus – at […]
Read MoreInsulin delivery device maker Beta Bionics (BBNX) increased its IPO’s size to 12.0 million shares – up from 10.0 million shares – and priced the IPO at $17.00 – the top of its range – to raise $204.0 million on Wednesday night, Jan. 29, 2025. At pricing, Beta Bionics had a market cap of $729.13 million. (This column, […]
Read More